Dong-Sook Kim1, Hyun Jung Kim2, Hyeong Sik Ahn3. 1. Department of Research, Health Insurance Review and Assessment Service, Wonju, Republic of Korea. 2. Department of Preventive Medicine, College of Medicine, Korea University, 126-1, 5-ga, Anam-dong, Sungbuk-gu, Seoul, 136-705, Republic of Korea. 3. Department of Preventive Medicine, College of Medicine, Korea University, 126-1, 5-ga, Anam-dong, Sungbuk-gu, Seoul, 136-705, Republic of Korea. iebm.ku@gmail.com.
Abstract
BACKGROUND: This study investigated the association between the use of statins, the incidence of gastric, colorectal, and esophageal cancers, and mortality between January 2005 and June 2013 in South Korea. METHODS: We compared patients aged 45-70 years statin users for at least 6 months to non-statin users matched by age and sex, from 2004 to June 2013 using the National Health Insurance database. Main outcomes were gastric, colorectal, and esophageal cancer incidence and mortality. Cox proportional hazard regression was used to calculate the adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs) among overall cohort and matched cohort after propensity score matching with a 1:1 ratio. RESULTS: Out of 1,008,101 people, 20,473 incident cancers, 3938 cancer deaths occurred and 7669 incident cancer, 1438 cancer death in matched cohort. The aHRs for the association between the risk of cancers and statin use were 0.7 (95% CI 0.65-0.74) for gastric cancer, 0.73 (95% CI 0.69-0.78) for colorectal cancer, and 0.55 (95% CI 0.43-0.71) for esophageal cancer. There were associations between statin use and decreased gastric cancer mortality (HR 0.46, 95% CI 0.52-0.57), colorectal cancer mortality (HR 0.43, 95% CI 0.36-0.51), and esophageal cancer mortality (HR 0.41, 95% CI 0.27-0.50) in the overall cohort and this pattern was similar in the matched cohort. DISCUSSION: Statin use for at least 6 months was significantly associated with a lower risk of stomach, colorectal, and esophageal cancer incidence as well as cancer mortality after a diagnosis.
BACKGROUND: This study investigated the association between the use of statins, the incidence of gastric, colorectal, and esophageal cancers, and mortality between January 2005 and June 2013 in South Korea. METHODS: We compared patients aged 45-70 years statin users for at least 6 months to non-statin users matched by age and sex, from 2004 to June 2013 using the National Health Insurance database. Main outcomes were gastric, colorectal, and esophageal cancer incidence and mortality. Cox proportional hazard regression was used to calculate the adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs) among overall cohort and matched cohort after propensity score matching with a 1:1 ratio. RESULTS: Out of 1,008,101 people, 20,473 incident cancers, 3938 cancer deaths occurred and 7669 incident cancer, 1438 cancer death in matched cohort. The aHRs for the association between the risk of cancers and statin use were 0.7 (95% CI 0.65-0.74) for gastric cancer, 0.73 (95% CI 0.69-0.78) for colorectal cancer, and 0.55 (95% CI 0.43-0.71) for esophageal cancer. There were associations between statin use and decreased gastric cancer mortality (HR 0.46, 95% CI 0.52-0.57), colorectal cancer mortality (HR 0.43, 95% CI 0.36-0.51), and esophageal cancer mortality (HR 0.41, 95% CI 0.27-0.50) in the overall cohort and this pattern was similar in the matched cohort. DISCUSSION: Statin use for at least 6 months was significantly associated with a lower risk of stomach, colorectal, and esophageal cancer incidence as well as cancer mortality after a diagnosis.
Authors: Marzieh Araghi; Isabelle Soerjomataram; Mark Jenkins; James Brierley; Eva Morris; Freddie Bray; Melina Arnold Journal: Int J Cancer Date: 2019-01-08 Impact factor: 7.396
Authors: Marzieh Araghi; Isabelle Soerjomataram; Aude Bardot; Jacques Ferlay; Citadel J Cabasag; David S Morrison; Prithwish De; Hanna Tervonen; Paul M Walsh; Oliver Bucher; Gerda Engholm; Christopher Jackson; Carol McClure; Ryan R Woods; Nathalie Saint-Jacques; Eileen Morgan; David Ransom; Vicky Thursfield; Bjørn Møller; Suzanne Leonfellner; Marianne G Guren; Freddie Bray; Melina Arnold Journal: Lancet Gastroenterol Hepatol Date: 2019-05-16
Authors: Melina Arnold; Christian C Abnet; Rachel E Neale; Jerome Vignat; Edward L Giovannucci; Katherine A McGlynn; Freddie Bray Journal: Gastroenterology Date: 2020-04-02 Impact factor: 22.682
Authors: Marzieh Araghi; Melina Arnold; Mark J Rutherford; Marianne Grønlie Guren; Citadel J Cabasag; Aude Bardot; Jacques Ferlay; Hanna Tervonen; Lorraine Shack; Ryan R Woods; Nathalie Saint-Jacques; Prithwish De; Carol McClure; Gerda Engholm; Anna T Gavin; Eileen Morgan; Paul M Walsh; Christopher Jackson; Geoff Porter; Bjorn Møller; Oliver Bucher; Michael Eden; Dianne L O'Connell; Freddie Bray; Isabelle Soerjomataram Journal: Gut Date: 2020-06-01 Impact factor: 23.059
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702